Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 11/2013

01-11-2013 | Letter to the editor

Optimal control of nausea and vomiting with a three-drug antiemetic regimen with aprepitant in metastatic pancreatic cancer patients treated with first-line modified FOLFIRINOX

Authors: Nicola Silvestris, Anna Elisabetta Brunetti, Marco Russano, Patrizia Nardulli

Published in: Supportive Care in Cancer | Issue 11/2013

Login to get access

Excerpt

To the Editor …
Literature
1.
Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817–1825PubMedCrossRef
2.
Gralla RJ, de Wit R, Herrstedt J et al (2005) Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two phase III randomized clinical trials. Cancer 104:864–868PubMedCrossRef
3.
Poli-Bigelli S, Rodrigues-Pereira J et al (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97:3090–3098PubMedCrossRef
4.
5.
Nieva JJ, Webb W, Siuzdak G (2007) Pharmacokinetic effect of aprepitant on irinotecan in patients with colorectal cancer. In: ASCO annual meeting proceedings, abstract no. 19622. J Clin Oncol 25(18S)
Metadata
Title
Optimal control of nausea and vomiting with a three-drug antiemetic regimen with aprepitant in metastatic pancreatic cancer patients treated with first-line modified FOLFIRINOX
Authors
Nicola Silvestris
Anna Elisabetta Brunetti
Marco Russano
Patrizia Nardulli
Publication date
01-11-2013
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 11/2013
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-013-1944-y

Other articles of this Issue 11/2013

Supportive Care in Cancer 11/2013 Go to the issue

Original Article

Day One Talk: parent preferences when learning that their child has cancer

Editorial

The MASCC/ISOO Mucositis Guidelines: dissemination and clinical impact

Original Article

Surprising results regarding MASCC members' beliefs about spiritual care

Original Article

Determinants of quality of life in advanced cancer patients with bone metastases undergoing palliative radiation treatment

Review Article

Systematic review of miscellaneous agents for the management of oral mucositis in cancer patients

Original Article

Excess risk of Clostridium difficile infection in ovarian cancer is related to exposure to broad-spectrum antibiotics
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits